Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the ...

This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a full text component.

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Study presented at ESMO Breast 2025 finds specific gut bacteria and microbial enzymes may be linked to breast cancer ...

The chances of recurrence are particularly high during the first few years ... This means that 65 in every 100 patients of TNBC (that has spread) are alive after five years. For perspective, other ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

Thanks to advances in medical care, the chances of recurrence from triple-negative breast cancer have gone down significantly. However, statistics still show that Black women had an overall 4% higher ...

and menopausal status remain important in predicting recurrence. Additionally, exposure to pesticides emerged as a significant factor in our population study who recurred disease, linked to ...

New data support integrating tumor-infiltrating lymphocyte levels with nodal status to improve risk stratification in women with triple-negative breast cancer (TNBC) and pathological complete ...